Ronan Le Calloch
About
Ronan Le Calloch is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology.
According to data from OpenAlex, Ronan Le Calloch has authored 26 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 12 papers in Pathology and Forensic Medicine and 12 papers in Oncology. Recurrent topics in Ronan Le Calloch's work include Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Advanced Breast Cancer Therapies (3 papers). Ronan Le Calloch is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Advanced Breast Cancer Therapies (3 papers). Ronan Le Calloch collaborates with scholars based in France, Belgium and United States. Ronan Le Calloch's co-authors include David Ghez, Mathieu Dupont, Laëtitia Souchet, Caroline Dartigeas, Charles Herbaux, Franciane Paul, Marie‐Pierre Ledoux, Caroline Protin, Emmanuelle Ferrant and Brigitte Dreyfus and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.
In The Last Decade
Ronan Le Calloch
25 papers receiving 394 citations
Peers
Ronan Le Calloch
Cristina Estany Spain
Ernesta Audisio Italy
Rosario Varela Spain
Montserrat Rovira Spain
M. Essink Germany
Alexander Burchardt Germany
K. Delavigne France
Şeniz Öngören Türkiye
Lohith Gowda United States
Georgios Pongas United States
Citations per year, relative to Ronan Le Calloch Ronan Le Calloch (= 1×)
peers
Cristina Estany
Countries citing papers authored by Ronan Le Calloch
Since
Specialization
Citations
This map shows the geographic impact of Ronan Le Calloch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronan Le Calloch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronan Le Calloch more than expected).
Fields of papers citing papers by Ronan Le Calloch
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ronan Le Calloch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronan Le Calloch. The network helps show where Ronan Le Calloch may publish in the future.
Co-authorship network of co-authors of Ronan Le Calloch
This figure shows the co-authorship network connecting the top 25 collaborators of Ronan Le Calloch. A scholar is included among the top collaborators of Ronan Le Calloch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronan Le Calloch. Ronan Le Calloch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gouill, Steven Le, Virginie De Wilde, Toby A. Eyre, et al.. (2024). Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial. Blood. 144(Supplement 1). 745–745.
2.
Laribi, Kamel, Stéphanie Poulain, Lise Willems, et al.. (2024). Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO ). British Journal of Haematology. 204(6). 2233–2236.
3.
Galicier, Lionel, Nizar Mahlaoui, Claire Fieschi, et al.. (2024). Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies. Blood Advances. 8(24). 6171–6182.
4.
Leleu, Xavier, Nathalie Texier, Cyrille Touzeau, et al.. (2023). Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study. SHILAP Revista de lepidopterología. 5(1). 55–60.
5.
Ysebaert, Loïc, Xavier Troussard, Vincent Lévy, et al.. (2023). P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY. HemaSphere. 7(S3). e578244e–e578244e.
6.
Calloch, Ronan Le, Isabelle Quintin‐Roué, Adrian Tempescul, et al.. (2022). Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma. PubMed. 2. 829138–829138.
7.
Ysebaert, Loïc, Xavier Troussard, Vincent Lévy, et al.. (2022). Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study. Blood. 140(Supplement 1). 12395–12396.
8.
Laribi, Kamel, Stéphanie Poulain, Lise Willems, et al.. (2022). Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO). Blood. 140(Supplement 1). 3627–3628.
9.
Laribi, Kamel, Alix Baugier de Materre, Mohamad Sobh, et al.. (2020). Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Advances. 4(19). 4838–4848.
10.
Gall‐Ianotto, C. Le, Ronan Le Calloch, Aurélie Chauveau, et al.. (2019). Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis. Journal of Thrombosis and Haemostasis. 17(11). 1950–1955.
11.
Gendron, Nicolas, Flore Sicre de Fontbrune, Alice Guyard, et al.. (2019). Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature. Haematologica. 105(7). e333–e336.
12.
Ghez, David, Caroline Protin, Marine Baron, et al.. (2018). Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 131(17). 1955–1959.
13.
Bot, Audrey Le, Jean‐Philippe Talarmin, Ronan Le Calloch, et al.. (2018). Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?. Médecine et Maladies Infectieuses. 48(4). 294–297.
14.
Jaccard, Arnaud, Jean‐François Benoist, Lucile Couronné, et al.. (2018). Monitoring Asparaginase Activity in 21 Patients with Extranodal NK/T-Cell Lymphoma Shows a Very High Proportion of Asparaginase Inactivation. Blood. 132(Supplement 1). 5351–5351.
15.
Calloch, Ronan Le, Karine Lacut, C. Le Gall‐Ianotto, et al.. (2017). Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study). Haematologica. 103(4). 607–613.
16.
Calloch, Ronan Le, et al.. (2015). Mantle cells lymphoma: standards and news. Hématologie. 21(3). 169–176.
17.
Calloch, Ronan Le, et al.. (2013). Fungal arthritis of the hip in patient with aplastic anaemia. BMJ Case Reports. 2013. bcr2013008902–bcr2013008902.
18.
Cluzeau, Thomas, Nathalie Dhédin, Françoise Huguet, et al.. (2012). Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT). Blood. 120(21). 3561–3561.
19.
Eveillard, Jean‐Richard, Jean‐Christophe Ianotto, Adrian Tempescul, et al.. (2011). Favorable Impact of Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 on Overall Survival and Progression-Free Survival in Advanced Stage or Relapsed/Refractory Follicular Lymphoma: Results of a Phase II Study. Blood. 118(21). 3066–3066.
20.
Eveillard, Jean‐Richard, Jean‐Christophe Ianotto, Adrian Tempescul, et al.. (2010). Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 In Poor-Risk DLBCL: Results of a Phase II Study. Blood. 116(21). 3558–3558.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Cristina Estany Breakdown of academic impact, for papers by Ernesta Audisio Breakdown of academic impact, for papers by Rosario Varela Breakdown of academic impact, for papers by Montserrat Rovira Breakdown of academic impact, for papers by M. Essink Breakdown of academic impact, for papers by Alexander Burchardt Breakdown of academic impact, for papers by K. Delavigne Breakdown of academic impact, for papers by Şeniz Öngören Breakdown of academic impact, for papers by Lohith Gowda Breakdown of academic impact, for papers by Georgios Pongas